Boston Scientific to acquire Penumbra for $14.5bn.

Boston Scientific, a manufacturer of medical devices, agreed to acquire Penumbra, a global healthcare company, for $14.5bn. "Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space. I'm thrilled to combine the talents and shared values of our teams – including welcoming Penumbra's chairman and chief executive officer, Adam Elsesser, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation," Mike Mahoney, Boston Scientific Chairman and CEO.